Glaxo's Zantac EFFERdose
This article was originally published in The Tan Sheet
Executive Summary
Effervescent ranitidine tablets and granules in 150 mg strength will enter the U.S. market in June. EFFERdose was approved March 31. Another "easy to swallow" line extension, Zantac GELdoes soft gelatin capsules (150 and 300 mg), was approved March 8 and launched May 16. The effervescent and gelatin forms could become delivery systems for an OTC version of the ulcer drug, which is under development...
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning